Serum osteoprotegerin is increased and predicts survival in idiopathic pulmonary arterial hypertension (Q35929743)

11 August 2017

Serum osteoprotegerin is increased and predicts survival in idiopathic pulmonary arterial hypertension (English)

1 reference

idiopathic pulmonary arterial hypertension

11 August 2017

0 references

Abdul G Hameed

5

0 references

Elaine Soon

Elaine Soon

7

0 references

Allan Lawrie

Allan Lawrie

17

0 references

Nicholas W Morrell

Nicholas W Morrell

15

0 references

Joanna Pepke-Zaba

9

Joanna Pepke-Zaba

1 reference

11 August 2017

8

Carmen Treacy

1 reference

11 August 2017

Robin Condliffe

1

1 reference

11 August 2017

Josephine A Pickworth

2

1 reference

11 August 2017

Kay Hopkinson

3

1 reference

11 August 2017

Sara J Walker

4

1 reference

11 August 2017

Jay Suntharaligam

6

1 reference

11 August 2017

Sheila E Francis

10

1 reference

11 August 2017

David C Crossman

11

1 reference

11 August 2017

Christopher M H Newman

12

1 reference

11 August 2017

Charles A Elliot

13

1 reference

11 August 2017

Allison C Morton

14

1 reference

11 August 2017

David G Kiely

16

1 reference

11 August 2017

1 January 2012

1 reference

11 August 2017

Pulmonary circulation

1 reference

11 August 2017

2

1 reference

11 August 2017

1

1 reference

11 August 2017

21-27

1 reference

Paigen diet-fed apolipoprotein E knockout mice develop severe pulmonary hypertension in an interleukin-1-dependent manner

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342744

Increased levels of bone remodeling biomarkers (osteoprotegerin and osteopontin) in hypertensive individuals

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342744

Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342744

Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the In

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342744

Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342744

Pathologic assessment of vasculopathies in pulmonary hypertension

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342744

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342744

Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342744

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342744

Elevated serum osteoprotegerin levels measured early after acute ST-elevation myocardial infarction predict final infarct size

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342744

Prognostic value of osteoprotegerin in chronic heart failure: The GISSI-HF trial

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342744

The tumour necrosis factor-related apoptosis-inducing ligand-osteoprotegerin system in limited systemic sclerosis: a new disease marker?

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342744

Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342744

Patients with pulmonary hypertension related to congenital systemic-to-pulmonary shunts are characterized by inflammation involving endothelial cell activation and platelet-mediated inflammation.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342744

Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342744

Epoprostenol therapy decreases elevated circulating levels of monocyte chemoattractant protein-1 in patients with primary pulmonary hypertension

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3342744

Dysfunctional Smad Signaling Contributes to Abnormal Smooth Muscle Cell Proliferation in Familial Pulmonary Arterial Hypertension

24 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.4103%2F2045-8932.94819

Elevated Levels of Inflammatory Cytokines Predict Survival in Idiopathic and Familial Pulmonary Arterial Hypertension

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.4103%2F2045-8932.94819

Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure

21 January 2018

1 reference

12 December 2020

Osteoprotegerin is associated with markers of atherosclerosis and body fat mass in type 2 diabetes patients

1 reference

12 December 2020

Primary pulmonary hypertension

1 reference

12 December 2020

Soluble receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis: OPG is associated with poor physical mobility and reflects systemic inflammation

1 reference

12 December 2020

Serum osteoprotegerin and tumor necrosis factor related apoptosis inducing-ligand (TRAIL) are elevated in type 2 diabetic patients with albuminuria and serum osteoprotegerin is independently associated with the severity of diabetic nephropathy

1 reference

12 December 2020

Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes

1 reference

12 December 2020

Identifiers

DOI

10.4103/2045-8932.94819

1 reference

11 August 2017

1 reference

11 August 2017

1 reference